MedImmune Oncology

AstraZeneca Oncology, which incorporates the legacy biologics expertise of MedImmune, is a global leader in the development and commercialization of innovative cancer therapies. The company focuses on four primary scientific pillars: Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, and Antibody-Drug Conjugates. Its commercial portfolio includes blockbuster treatments such as Imfinzi (durvalumab), Tagrisso (osimertinib), and Lynparza (olaparib), which have redefined standards of care in lung, breast, and ovarian cancers. The division maintains a deep clinical pipeline exploring novel modalities, including bispecific antibodies and cell therapies, often through strategic collaborations. Following the 2019 retirement of the MedImmune brand, these operations are fully integrated into AstraZeneca's unified R&D structure.